Back to Search Start Over

Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells.

Authors :
Hideshima, Teru
Catley, Laurence
Raje, Noopur
Chauhan, Dharminder
Podar, Klaus
Mitsiades, Constantine
Tai, Yu-Tzu
Vallet, Sonia
Kiziltepe, Tanyel
Ocio, Enrique
Ikeda, Hiroshi
Okawa, Yutaka
Hideshima, Hiromasa
Munshi, Nikhil C.
Yasui, Hiroshi
Richardson, Paul G.
Anderson, Kenneth C.
Source :
British Journal of Haematology. Sep2007, Vol. 138 Issue 6, p783-791. 9p. 2 Black and White Photographs, 1 Diagram, 3 Graphs.
Publication Year :
2007

Abstract

Akt mediates growth and drug resistance in multiple myeloma (MM) cells in the bone marrow (BM) microenvironment. We have shown that a novel Akt inhibitor Perifosine induces significant cytotoxicity in MM cells in the BM milieu. This study further delineated molecular mechanisms whereby Perifosine triggered cytotoxicity in MM cells. Neither the intensity of Jun NH2-terminal kinase phosphorylation nor caspase/poly (ADP-ribose) polymerase cleavage correlated with Perifosine-induced cytotoxicity in MM.1S, INA6, OPM1 and OPM2 MM cells. However, survivin, which regulates caspase-3 activity, was markedly downregulated by Perifosine treatment, without changes in other anti-apoptotic proteins. Downregulation of survivin by siRNA significantly inhibited OPM1 MM cell growth, confirming that survivin mediates MM cell survival. Perifosine significantly downregulated both function and protein expression of β-catenin. Co-culture with BM stromal cells (BMSCs) upregulated both β-catenin and survivin expression in MM cells, which was blocked by Perifosine. Importantly, Perifosine treatment also downregulated survivin expression in human MM cells grown in vivo in a severe combined immunodeficient mouse xenograft model. Finally, Perifosine inhibited bortezomib-induced upregulation of survivin, associated with enhanced cytotoxicity of combined bortezomib and Perifosine treatment. These preclinical studies provide the framework for clinical trials of bortezomib with Perifosine to improve patient outcome in MM. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
00071048
Volume :
138
Issue :
6
Database :
Academic Search Index
Journal :
British Journal of Haematology
Publication Type :
Academic Journal
Accession number :
26313851
Full Text :
https://doi.org/10.1111/j.1365-2141.2007.06714.x